Considering the Host in Host-pathogen Interactions
Overview
Overview
Affiliations
Affiliations
Soon will be listed here.
References
1.
Pahil K, Gilman M, Baidin V, Clairfeuille T, Mattei P, Bieniossek C
. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature. 2024; 625(7995):572-577.
PMC: 10794137.
DOI: 10.1038/s41586-023-06799-7.
View
2.
Zampaloni C, Mattei P, Bleicher K, Winther L, Thate C, Bucher C
. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024; 625(7995):566-571.
PMC: 10794144.
DOI: 10.1038/s41586-023-06873-0.
View
3.
Lowy I, Molrine D, Leav B, Blair B, Baxter R, Gerding D
. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197-205.
DOI: 10.1056/NEJMoa0907635.
View
4.
Williams K, Guerrero S, Flores-Garcia Y, Kim D, Williamson K, Siska C
. A candidate antibody drug for prevention of malaria. Nat Med. 2024; 30(1):117-129.
PMC: 10803262.
DOI: 10.1038/s41591-023-02659-z.
View
5.
Fumagalli V, Rava M, Marotta D, Di Lucia P, Bono E, Giustini L
. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat Immunol. 2024; 25(4):633-643.
PMC: 11003867.
DOI: 10.1038/s41590-024-01787-z.
View